Diavil 50 mg (Tablet)

Unit Price: ৳ 20.00 (3 x 10: ৳ 600.00)
Strip Price: ৳ 200.00

Medicine Details

Category Details
Generic Vildagliptin
Company Biopharma limited

Indications

  • Adjunct to diet and exercise
  • Improves glycemic control in type 2 diabetes mellitus
  • Monotherapy
  • Dual combination therapy with Metformin, Sulphonylurea, Thiazolidinedione, or Insulin

Pharmacology

  • Dipeptidyl peptidase-4 (DPP-4) inhibitor
  • Slows inactivation of incretin hormones
  • Increases insulin release in a glucose-dependent manner
  • Decreases glucagon levels in a glucose-dependent manner

Dosage & Administration

  • Recommended dose: 50 mg or 100 mg daily for monotherapy
  • Recommended dose: 50 mg twice daily in dual combination with Metformin or Thiazolidinedione
  • Recommended dose: 50 mg once daily in the morning in dual combination with a Sulphonylurea
  • May be taken with or without a meal
  • No dosage adjustment required in elderly or patients with mild renal impairment
  • Not recommended in patients under 18 years of age

Interaction

  • No interactions with pioglitazone, metformin, glibenclamide, digoxin, warfarin, amlodipine, ramipril, valsartan, or simvastatin
  • Glucose-lowering effect may be reduced by thiazides, corticosteroids, thyroid products, and sympathomimetics

Contraindications

  • Hypersensitivity to the active substance or excipients
  • Moderate to severe renal impairment
  • Hepatic impairment: pre-treatment ALT or AST > 3 times the upper limit of normal (ULN)
  • Type 1 diabetes

Side Effects

  • Majority of adverse reactions are mild and transient
  • Rare case of hepatic dysfunction

Pregnancy & Lactation

  • Not to be used in pregnancy
  • Not to be used during lactation

Precautions & Warnings

  • Caution in patients aged 75 years and older
  • Monitoring of LFTs prior to initiation and at three-monthly intervals in the first year
  • Frequent monitoring of liver function tests if transaminase levels are increased
  • Discontinue treatment if AST or ALT persists at 3xULN
  • Discontinue treatment if patients develop jaundice or signs of liver dysfunction
  • Do not reinitiate treatment after withdrawal
  • Use with caution in patients with congestive heart failure of NYHA functional class I-II
  • Do not use in patients with NYHA functional class III IV

Therapeutic Class

  • Dipeptidyl Peptidase-4 (DPP-4) inhibitor

Storage Conditions

  • Store below 30°C
  • Keep away from light and moisture
  • Keep out of reach of children

Related Brands